Wei-Hsuan Lo-Ciganic1,2, Walid F Gellad2,3,4, Adam J Gordon2,3,4, Gerald Cochran2,5, Michael A Zemaitis2,6, Terri Cathers7, David Kelley7, Julie M Donohue2,8. 1. Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA. 2. Center for Pharmaceutical, Policy and Prescribing, Health Policy Institute, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 4. Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, USA. 5. School of Social Work, University of Pittsburgh, Pittsburgh, PA, USA. 6. Department of Pharmaceutical Science, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. 7. Pennsylvania Department of Human Services, Harrisburg, PA, USA. 8. Department of Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
BACKGROUND AND AIMS: Uncertainty about optimal treatment duration for buprenorphine opioid agonist therapy may lead to substantial variation in provider and payer decision-making regarding treatment course. We aimed to identify distinct trajectories of buprenorphine use and examine outcomes associated with these trajectories to guide health system interventions regarding treatment length. DESIGN: Retrospective cohort study. SETTING: US Pennsylvania Medicaid. PATIENTS: A total of 10 945 enrollees aged 18-64 years initiating buprenorphine treatment between 2007 and 2012. MEASUREMENTS: Group-based trajectory models were used to identify trajectories based on monthly proportion of days covered with buprenorphine in the 12 months post-treatment initiation. We used separate multivariable Cox proportional hazard models to examine associations between trajectories and time to first all-cause hospitalization and emergency department (ED) visit within 12 months after the first-year treatment. FINDINGS: Six trajectories [Bayesian information criterion (BIC) = -86 246.70] were identified: 24.9% discontinued buprenorphine < 3 months, 18.7% discontinued between 3 and 5 months, 12.4% discontinued between 5 and 8 months, 13.3% discontinued > 8 months, 9.5% refilled intermittently and 21.2% refilled persistently for 12 months. Persistent refill trajectories were associated with an 18% lower risk of all-cause hospitalizations [hazard ratio (HR) = 0.82, 95% confidence interval (CI) = 0.70-0.95] and 14% lower risk of ED visits (HR = 0.86, 95% CI = 0.78-0.95) in the subsequent year, compared with those discontinuing between 3 and 5 months. CONCLUSIONS: Six distinct buprenorphine treatment trajectories were identified in this population-based low-income Medicaid cohort in Pennsylvania, USA. There appears to be an association between persistent use of buprenorphine for 12 months and lower risk of all-cause hospitalizations/emergency department visits.
BACKGROUND AND AIMS: Uncertainty about optimal treatment duration for buprenorphine opioid agonist therapy may lead to substantial variation in provider and payer decision-making regarding treatment course. We aimed to identify distinct trajectories of buprenorphine use and examine outcomes associated with these trajectories to guide health system interventions regarding treatment length. DESIGN: Retrospective cohort study. SETTING: US Pennsylvania Medicaid. PATIENTS: A total of 10 945 enrollees aged 18-64 years initiating buprenorphine treatment between 2007 and 2012. MEASUREMENTS: Group-based trajectory models were used to identify trajectories based on monthly proportion of days covered with buprenorphine in the 12 months post-treatment initiation. We used separate multivariable Cox proportional hazard models to examine associations between trajectories and time to first all-cause hospitalization and emergency department (ED) visit within 12 months after the first-year treatment. FINDINGS: Six trajectories [Bayesian information criterion (BIC) = -86 246.70] were identified: 24.9% discontinued buprenorphine < 3 months, 18.7% discontinued between 3 and 5 months, 12.4% discontinued between 5 and 8 months, 13.3% discontinued > 8 months, 9.5% refilled intermittently and 21.2% refilled persistently for 12 months. Persistent refill trajectories were associated with an 18% lower risk of all-cause hospitalizations [hazard ratio (HR) = 0.82, 95% confidence interval (CI) = 0.70-0.95] and 14% lower risk of ED visits (HR = 0.86, 95% CI = 0.78-0.95) in the subsequent year, compared with those discontinuing between 3 and 5 months. CONCLUSIONS: Six distinct buprenorphine treatment trajectories were identified in this population-based low-income Medicaid cohort in Pennsylvania, USA. There appears to be an association between persistent use of buprenorphine for 12 months and lower risk of all-cause hospitalizations/emergency department visits.
Authors: Herbert C Duber; Isabel A Barata; Eric Cioè-Peña; Stephen Y Liang; Eric Ketcham; Wendy Macias-Konstantopoulos; Shawn A Ryan; Mark Stavros; Lauren K Whiteside Journal: Ann Emerg Med Date: 2018-06-05 Impact factor: 5.721
Authors: Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet Journal: J Subst Abuse Treat Date: 2016-12-30
Authors: Bradley D Stein; Mark Sorbero; Andrew W Dick; Rosalie Liccardo Pacula; Rachel M Burns; Adam J Gordon Journal: JAMA Date: 2016-09-20 Impact factor: 56.272
Authors: Zoe M Weinstein; Debbie M Cheng; Maria J D'Amico; Leah S Forman; Danny Regan; Alexandra Yurkovic; Jeffrey H Samet; Alexander Y Walley Journal: Drug Alcohol Depend Date: 2020-05-25 Impact factor: 4.492